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Abstract  The past decade has seen several critical advances in our understanding of hypothalamic–pituitary–adrenal (HPA) axis regulation. 
Homeostatic physiological circuits need to integrate multiple internal and external stimuli and provide a dynamic output appropriate for the 
response parameters of their target tissues. The HPA axis is an example of such a homeostatic system. Recent studies have shown that circadian 
rhythmicity of the major output of this system—the adrenal glucocorticoid hormones corticosterone in rodent and predominately cortisol in 
man—comprises varying amplitude pulses that exist due to a subhypothalamic pulse generator. Oscillating endogenous glucocorticoid signals in-
teract with regulatory systems within individual parts of the axis including the adrenal gland itself, where a regulatory network can further modify 
the pulsatile release of hormone. The HPA axis output is in the form of a dynamic oscillating glucocorticoid signal that needs to be decoded at the 
cellular level. If the pulsatile signal is abolished by the administration of a long-acting synthetic glucocorticoid, the resulting disruption in physio-
logical regulation has the potential to negatively impact many glucocorticoid-dependent bodily systems. Even subtle alterations to the dynamics 
of the system, during chronic stress or certain disease states, can potentially result in changes in functional output of multiple cells and tissues 
throughout the body, altering metabolic processes, behavior, affective state, and cognitive function in susceptible individuals. The recent devel-
opment of a novel chronotherapy, which can deliver both circadian and ultradian patterns, provides great promise for patients on glucocorticoid 
treatment. Endocrine Reviews 41: 470 – 490, 2020)
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Review
T he hypothalamic–pituitary–adrenal (HPA) axis is a neurohormonal system 
that is critical for life. It is a multisystem axis that 
utilizes feed-forward and feedback loops to reg-
ulate glucocorticoid hormone levels within the 
physiological range appropriate for system ho-
meostasis. This is an equilibrium control system 
we have called continuous dynamic equilibration 
(1). This system has widespread effects in many 
body systems and not only regulates circadian 
metabolic, cognitive, cardiovascular, and immu-
nological behavior, but is also vital for protective 
responsive to both internal and external stressors. 
In order to fulfil these many disparate roles, the 
HPA axis needs several hallmark features. These 
include (1) anticipatory activation to prepare the 
animal for the active phase of the day (daytime 
for man and night time for nocturnal animals in-
cluding most rodent species). It also needs to be 
(2) sensitive to environmental perturbations, and 
to be able to respond differentially to small and 
large stimuli. This responsiveness must be (3) ro-
bust with preservation of dynamic behavior during 
these perturbations. Finally the system must 
show (4) plasticity to facilitate adaptation to new 
circumstances. This concept of dynamic regulation 
in endocrinology refines the older concept of ho-
meostasis toward a steady-state set point to a more 
dynamic understanding of how systems oscillate 
around an equilibrium position and how this allows 
for a reactive and adaptive system. Furthermore, it 
provides a conceptual basis for how allostasis—a 
new dynamic equilibrium position in response to 
novel circumstances—can lead to physiological 
change and disease. With these thoughts in mind 
our review will bring together new concepts of 
continuous dynamic equilibration, and how these 
provide the basis for understanding the impor-
tance of both circadian and ultradian rhythmicity 
for a responsive and adaptive HPA axis.
Organization of the 
Hypothalamic–Pituitary–Adrenal axis
Within the hypothalamus, the parvocellular 
neurons of the paraventricular nucleus (PVN) are 
a group of densely packed neurons that are highly 
responsive to external physiological stimuli such 
as altered light/dark cycle, or the presence of real 
or perceived stress (2,3), as shown in Fig. 1. These 
cells project to the capillaries of the median em-
inence, where they secrete corticotropin-releasing 
hormone (CRH) (and AVP) directly into the portal 
system and thence pituitary corticotrophs to regu-
late adrenocorticotropin (ACTH) secretion. Other 
parvocellular preautonomic neurons project to the 
brainstem and spinal cord, to regulate appetite and 
autonomic functions and suppress nociception, 
promoting analgesic effects (4). Magnocellular 
neurons of the PVN project directly to the poste-
rior pituitary to release both vasopressin and oxy-
tocin into the systemic circulation (5,6).
CRH and AVP released by parvocellular 
neurosecretory cells into hypothalamic capillaries 
that join infundibular blood vessels and reach a 
second capillary bed in the anterior pituitary to 
target anterior pituitary corticotroph cells where 
they stimulate the release of ACTH. This travels in 
the systemic circulation to reach the zona fasciculata 
of the adrenal cortex to activate the synthesis and 
subsequent release of glucocorticoid hormones (7).
Essential points
 • Pulsatile glucocorticoid production arises due to a subhypothalamic pulse generator and is the intrinsic property of the 
feed-forward feedback interplay between the pituitary and adrenal glands
 • The pulsatile hormone signal is decoded at the cellular level by the intracellular glucocorticoid receptor (GR), the 
mineralocorticoid receptor (MR), or both GR and MR in cell types where the 2 are coexpressed
 • Long-standing models of GR and MR working in collaboration and in opposition have retained their validity for the most 
part, with recent evidence for a role of MR in increasing GR transactivation potential during pulsatile glucocorticoid 
treatment, via a tethering mechanism
 • Pulsatile glucocorticoids have now been demonstrated to be required for optimal HPA physiological responses, stress-
coping behavior, complex cognitive processing, glutamatergic neurotransmission, synaptic metaplasticity, and emotional 
processing in man and experimental rodents
 • As glucocorticoid ultradian dynamics are altered in myriad disease states, as well as during synthetic glucocorticoid 
treatment and glucocorticoid replacement therapy, the resulting effects of GR- and MR-expressing cells and tissues can 
induce detrimental effects on physiological, cognitive, and behavioral function
 • Strategies to normalize circadian and ultradian endogenous glucocorticoid rhythms—along with more refined 
chronotherapies that are able to integrate both circadian and ultradian rhythms into their design—are currently being 
developed and show great promise
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Dynamics Within the HPA Axis in Health
An ultradian pattern of cortisol release in humans 
has been widely reported (8–12). More recently, 
the development of an automated sampling system 
for use in humans has enabled blood sampling at a 
higher frequency than has been previously possible 
(13). Fig. 1B shows a 24-hour profile of ACTH and 
cortisol in a healthy volunteer. With 10 minutes 
of sampling resolution, a short delay is evident 
between ACTH and cortisol secretion, with each 
cortisol pulse closely following each ACTH pulse. 
In healthy male subjects, Russell et  al. showed 
that both ACTH and cortisol pulsatility was rap-
idly inhibited by intravenous infusion of the syn-
thetic mixed glucocorticoid agonist prednisolone 
(14). The site of the rapid inhibition of ACTH 
secretion appears to be the anterior pituitary, as 
prednisolone also inhibited the ability of exoge-
nous CRH to induce increased ACTH and cor-
tisol secretion. Prednisolone fast feedback could be 
reduced by pretreatment with the glucocorticoid 
receptor (GR) antagonist mifepristone but not with 
the mineralocorticoid receptor (MR) antagonist 
spironolactone. The rapid dynamics of negative 
feedback on ACTH secretion were consistent with 
the plethora of evidence for a ligand-dependent 
nongenomic GR-mediated negative feedback in the 
anterior pituitary (15). The pituitary is not the only 
site where rapid nongenomic negative feedback is 
found, as Tasker and colleagues have elucidated a 
mechanism of glucocorticoid suppression by the 
hypothalamic endocannabinoid system (16–18).
This circadian and ultradian rhythm of ad-
renal glucocorticoid secretion has not only been 
recorded in man, but also in every other species 
tested so far, including rat (19–24) as shown in 
Fig. 1C, rhesus monkey (25–27), hamster (28,29), 
horse (30), sheep (31–33), and goat (34–36). A ro-
dent automated blood sampling system designed to 
perform frequent sampling on freely behaving rats 
in their home cage environment (1,37) has revealed 
the ultradian rhythm of rats in great detail, showing 
distinct pulses at approximately hourly intervals. 
The ultradian corticosterone rhythm of rats has 
been found to exhibit significant sex differences 
(38–41), and is subject to further change during 
lactation and aging (42–44), as a result of early 
life stress (45) and inflammatory disease (46,47). 
The HPA axis has also been found to exhibit re-
markable plasticity associated with physiological 
changes throughout life in healthy humans. An ex-
ample of HPA axis adaptation to rapidly changing 
physiology occurs during pregnancy. The maternal 
HPA axis undergoes dramatic activation during 
pregnancy resulting in increased circulating cor-
tisol, and a study at the Edinburgh Royal Infirmary 
was able to quantitatively assess this phenomenon 
using multiple peripheral blood and 24-hour inter-
stitial fluid samples on 5 healthy pregnant women 
at 16 to 24 weeks’ gestation (P1) and again at 30 to 
36 weeks’ gestation (P2) compared with a control 
group of healthy nonpregnant (NP) women. While 
an observed increase in cortisol pulse amplitude 
was not significantly different (NP 44 nmol/L, P1 
99  nmol/L, P2 131  nmol/L; P = .09), significant 
Corticosterone
ACTH
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Pituitary
gland
CRH
(b)(a)
(c)
Cortisol (CORT)
ACTHPVN
Adrenal
gland
Glucocorticoids
Figure 1. The HPA axis and its hormonal output over the day. (A) A schematic of the HPA axis. CRH (and AVP) are secreted from the 
PVN. These hormones in turn, stimulate the secretion of ACTH from the anterior pituitary, which in turn, drives the secretion of gluco-
corticoids from the adrenal cortex. Automated blood sampling has enabled high resolution measurements of the circadian and ultradian 
profile of (B) ACTH and cortisol (CORT) in human over a 24-hour period and (C) corticosterone in rat.
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differences were found in the increased fasting 
serum cortisol (NP 302nmol/L, P1 528 nmol/L, P2 
779  nmol/L; P = .018) as well as in the increased 
frequency of the cortisol pulses (NP 1.1 pulses/
hour, P1 1.5 pulses/hour, P2 1.6 pulses/hour 
P < .0001) (48). As human automated sampling 
methodologies become more refined (49,50), there 
will be far more detailed information about which 
features of the HPA axis are conserved between 
humans and experimental rodents, and where spe-
cies specific differences exist.
There are very clear similarities in the regula-
tion of HPA dynamics found in experimental ro-
dent studies and clinical studies in man. Consistent 
with the dynamics of the pituitary adrenal system 
observed in man (13), each pulse of ACTH is 
followed by a pulse of corticosterone in the rat (35). 
Similar to the human study findings, exogenous 
glucocorticoids exert a rapid inhibition of both 
basal and CRH-induced ACTH and corticosterone 
secretion (51–55) indicating the anterior pituitary 
as the primary site of rapid negative feedback.
The pulse generator
The general notion of a hypothalamic pulse gen-
erator prevailed until quite recently (56), despite 
strong evidence to the contrary from elegant 
studies in sheep which demonstrated ultradian 
pulses of ACTH and cortisol persisted after hy-
pothalamic pituitary disconnection (33). Walker 
et al. (57) used their rodent data to come up with 
a mathematical model that concluded endoge-
nous glucocorticoid pulses must arise due to the 
intrinsic relationship between the feed-forward 
signal from the anterior pituitary to the adrenal 
and the feedback signal from the adrenal to the an-
terior pituitary. Fig. 2 shows the model predicting 
that even a constant input of CRH will result in 
oscillations of ACTH and glucocorticoids, due to 
the inherent delay which exists in both the for-
ward part and the reverse part of the loop. This 
was tested with a constant CRH infusion in the 
rat (58). As predicted by the model, ACTH and 
corticosterone pulsatility could be experimen-
tally reinstated without a pulsatile CRH signal. 
Instead, pulsatile ACTH and subsequent pulsa-
tile corticosterone was found to be entirely de-
pendent upon the level of CRH rather than the 
pattern, as predicted by the mathematical model. 
Very low level CRH infusions were unable to in-
duce any detectable activity, while very high CRH 
levels produced disrupted pulsatile pituitary ad-
renal activity. Constant CRH infusion, at a dose 
that was more closely matched to physiological 
circadian peak levels, was able to induce ACTH 
and corticosterone oscillations with the time delay 
predicted by the mathematical model.
Dynamic regulation at the systems level
Although the pituitary–adrenal interaction is the 
mechanism underlying ultradian rhythmicity, hypo-
thalamic modulation of the HPA axis is the dominant 
factor regulating pulse amplitude over the course of 
each day. Circadian rhythms in activity, body temper-
ature, and hormonal systems are tightly controlled by 
the central circadian pacemaker, the suprachiasmatic 
nucleus (SCN) in the hypothalamus, which receives 
light cues via the retinal projections to entrain to a 
24-hour rhythm (59,60). Consistent with this, circa-
dian modulation of the amplitude of corticosterone 
pulses was profoundly affected by SCN lesion and 
constant light exposure in rats (61). Notably, the cir-
cadian nadir appeared to become “disinhibited” in a 
manner that was consistent with the described role 
for the SCN in HPA inhibition during the light phase 
in the nocturnal rat. In rat, GABAergic interneurons 
exert inhibitory tone on the PVN to decrease CRH 
release during the circadian nadir. In contrast, in di-
urnal species such as man, increased CRH release 
is hypothesized to be the result of excitatory input 
from glutamatergic interneurons (62,63). The SCN 
has also been shown to directly modulate adrenal 
sensitivity via autonomic nervous system innerva-
tion by the splanchnic nerve. Elegant experiments by 
Jasper and Engeland in the 1990s demonstrated that 
splanchnic denervation in the rat resulted in a loss 
in the circadian glucocorticoid nadir (22) with high 
amplitude pulses throughout the day, similar to that 
observed in SCN lesioned rats. Splanchnic denerva-
tion also increased the adrenal response to ACTH 
(24). These data taken together strongly indicate that 
the neural pathway, mapped in rat, from the SCN via 
the autonomic PVN and splanchnic nerve to the ad-
renal gland is inhibitory. There also appears to be a 
more direct effect of light on corticosterone secretion 
which is wavelength dependent (64).
Intra-adrenal dynamics
One of the key properties of the pituitary adrenal 
interaction is the inherent delay in ACTH-induced 
glucocorticoid release from the zona fasciculata 
of the adrenal cortex. This is because glucocorti-
coid hormones, lipophilic molecules, cannot be 
stored in vesicles but require de novo synthesis by 
steroidogenesis. For each pulsatile secretory event, 
steroidogenesis is initiated by ACTH binding to the 
cell surface G-protein coupled melanocortin type-2 
receptor (MC2R) (65), which activates a signaling 
cascade of 3′,5′-cyclic AMP, protein kinase A, 
hormone-sensitive lipase, and steroidogenic acute 
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regulatory protein (StAR), resulting in transfer of 
cholesterol to the inner mitochondrial membrane 
where it is rapidly converted to glucocorticoids via 
a series of enzymatic conversions (66). The first 
and rate-limiting enzyme in this process is cyto-
chrome P450 side chain cleavage enzyme (67,68), 
which catalyzes the conversion of cholesterol to 
pregnenolone for subsequent rapid conversion 
steps through progesterone to 11-deoxycortisol 
to cortisol, or alternatively through progesterone 
to 11-deoxycorticosterone to corticosterone. In 
humans, cortisol is the predominant glucocorticoid 
produced. In rats, corticosterone is the predomi-
nant glucocorticoid produced instead of cortisol, 
due to the lack of 17 alpha-hydroxylase (66).
Spiga et  al. have elucidated a complex regu-
latory network, which acts together with cAMP 
response-element binding protein (CREB), notably 
including the positive regulators SF-1 and Nur77, 
and the negative regulator Dosage-sensitive sex re-
versal, adrenal hypoplasia congenita, critical region 
on the X chromosome, gene-1 (DAX-1) as shown in 
Fig. 3 (69). Elegant time course studies have shown, 
both in vivo (69) and in zona fasciculata (ZF) model 
cell lines ATC1 and ATC7 (70), that the phospho-
rylation of steroidogenic proteins follow an ultra-
dian rhythm. Pulses of ACTH can induce pulses 
of corticosterone secretion in HPA axis-suppressed 
rats, whereas the same dose delivered in a constant 
infusion fails to induce pulsatile corticosterone se-
cretion (71). The mechanism was further explored 
in the ZF cell lines (70) where it was found that con-
stant ACTH treatment induced larger increases in 
pCREB and steroidogenic gene transcription at the 
start of treatment but the cells became unresponsive 
to the stimuli over time. Continuing responsiveness 
over several hours was achieved with pulsatile ACTH 
application, further supporting the conclusion that 
pulsatile ACTH is required for optimal regulation 
of steroidogenesis in adrenal ZF cells. In addition 
to this rapid steroidogenic pathway for synthesizing 
glucocorticoids in pulses, ACTH also induces tran-
scription of many genes including MC2R, StAR, and 
CYP11A1 (the gene encoding cytochrome P450 side 
chain cleavage enzyme) to presumably replenish the 
cellular store of steroidogenic pathway components.
There is also an inherent short delay in the neg-
ative feedback part of the loop. Once synthesized, 
glucocorticoids rapidly travel through the circu-
lation to inhibit the HPA axis at the level of the 
hypothalamus and anterior pituitary, inhibiting 
synthesis and release of CRH (72–75) and ACTH 
(76–78), respectively. Recent data have fur-
ther implicated a novel intra-adrenal negative 
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Figure 2. Response of the pituitary–adrenal system to constant CRH drive. (A) Feed-forward feedback interplay between the pituitary 
and adrenal accounts for ultradian oscillations in glucocorticoid secretion. (B) Different combinations of constant CRH drive and delay 
can lead to 2 qualitatively different responses. On one side of the transition curve, when the CRH drive is low, the pituitary–adrenal system 
responds with constant levels in ACTH and glucocorticoid (C). On the other side of the transition curve, the pituitary–adrenal system 
responds with pulsatile fluctuations in the levels of ACTH and glucocorticoid, despite the fact that the CRH drive is constant (D). On the 
far right-hand side of the transition curve, when the CRH drive is highest, the pituitary–adrenal system again responds with constant levels 
in ACTH and glucocorticoid (E). Model predictions for ACTH (blue) and glucocorticoid (pink) are shown in C, D, and E. Walker et al. (57).
Walker JJ, Terry JR, Lightman SL. Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis. Proc Biol Sci 2010;277:1627–
1633. CC-BY OA. © 2010 Springer Nature.
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feedback loop involving GR, which may rapidly 
inhibit ACTH-induced steroidogenesis (79). 
Consistent with this hypothesis, Spiga et al. (69) 
have shown a rapid and transient activation of 
adrenal GR with each pulse of corticosterone 
synthesis. Interestingly, GR and SF-1 have been 
demonstrated to work together to increase ex-
pression of the steroidogenic inhibitor DAX-1, 
while ACTH disrupts this GR/SF-1 interaction 
(80). Therefore, the opposing actions of ACTH 
and intra-adrenal corticosterone on DAX-1 
are hypothesized to also contribute to the rapid 
oscillations in intra-adrenal steroidogenesis.
Decoding the Glucocorticoid Oscillating 
Signal at the Cellular Level
Endogenous mammalian glucocorticoid actions 
are mediated via 2 corticosteroid receptors. The 
high-affinity MR originally termed the type 1 cor-
ticosteroid receptor is encoded by the NR3C2 gene 
(81). The low-affinity GR originally termed the 
type 2 corticosteroid receptor is encoded by the 
NR3C1 gene (82).
GR and MR are classed with the steroid hormone 
receptors, which are a conserved subset of the nu-
clear receptor superfamily (83). Nuclear receptors 
are diverse in their functional output, controlling 
homeostasis, metabolism, and development. These 
receptors are ligand activated transcription factors, 
and following activation by hormone binding, the 
receptors bind to regulatory deoxyribonucleic acid 
(DNA) regions of target genes to initiate transcrip-
tional activation or repression. Nuclear receptors 
share sequence and structure similarity and com-
prise 3 major functional domains as shown in 
Fig.  4: The N-terminal domain (NTD), which 
contains the activation function domain 1 (AF1), 
and acts in a ligand-independent manner. A central 
Figure 3. The steroidogenic regulatory network. The synthesis of glucocorticoids in adrenocortical cells is governed at multiple levels 
by both genomic and nongenomic components indicated in this schematic. In order to constrain the complexity of the model only nodes 
shown to be involved in glucocorticoid-mediated feedback loops or in crosstalk with StAR are included. The model therefore consists 
of a set of delay differential equations (DDEs) that describes the ACTH stimulated dynamics of intra-adrenal glucocorticoid (A-CORT) 
levels and phosphorylation of GR (pGR, a marker of GR activation), and the expression of DAX-1, SF-1, and StAR. Symbology: σ accounts 
for the basal non-ACTH-dependent gene promoter activation rate. It is also more commonly known as “leaky transcription”. τ represents 
time delays, in this case, transcription and translation of each gene. ϕ represents degradation sinks for each molecular species, in this 
case heteronuclear RNAs (hnRNAs), mRNAs, and proteins. The model predicted that ACTH should modulate the half-life (stability or 
degradation rate) of Dax-1 mRNA, depicted here by the dashed line, and required in order to explain the data. μ represents a combination 
of 2 processes: the proteasome-mediated degradation of StARp37 as it progresses through the outer to inner mitochondrial membrane, 
and the import of StARp32 and StARp30 into mitochondria. ɛ represents the export rate of intra-adrenal glucocorticoid (A-CORT) out of 
adrenocortical cells. Spiga F, Zavala E, Walker JJ, Zhao Z, Terry JR, Lightman SL. Dynamic responses of the adrenal steroidogenic regulatory 
network. Proc Natl Acad Sci U S A 2017; 114:E6466-E6474. CC-BY OA © 2017 Springer Nature.
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DNA binding domain (DBD) and a C-terminal 
ligand-binding domain (LBD), containing the 
ligand-dependent activation function 2 (AF2) site, 
which is tightly regulated by hormone binding. The 
LBD is connected to the NTD by a hinge region, 
enabling the receptors to act as ligand-activated 
transcription factors, binding to specific DNA 
sequences and recruiting other factors via the 
AF sites to evoke a high level of transcriptional 
regulation.
The LBD consists of 12 helices that fold into 
a globular structure, each consisting of 3 sets of 
helices forming the sides and top of the globule, 
creating a central hydrophobic pocket where 
the ligand can bind. This structure is held in an 
open configuration by the association of chap-
erone proteins. The DBD contains 2 zinc finger 
motifs which are responsible for recognition and 
binding of both MR (84) and GR (85) to target re-
gions of DNA known as glucocorticoid response 
elements (GREs). The first zinc finger comprises 
a P-box with a glycine, serine, and valine that in-
teract with specificity to the GRE. The second 
zinc finger is required for receptor dimerization. 
Figure 4. Comparison of MR or GR homodimers bound to a GRE. The sequence of the element, along with the 2 bound half sites, is 
shown below the structure. (A) The structure of 2 MR DBDs (each monomer depicted in a different shade of green) bound to a 17 base 
pair GRE shows the asymmetric unit of the crystal structure (84). (B) The structure of the GR DBD (each monomer depicted in a different 
shade of orange) bound to a similar GRE, with the exception that it is derived from the structure of the GR DBD bound to the FKBP5 GRE 
(85). (C) The steroid receptors have a highly conserved protein domain structure. The % sequence identity is indicated for each domain, 
relative to hGR. The size of each protein is indicated on the schematic; hGRalpha 777 amino acids, MR 984 amino acids, PR 934 amino 
acids, AR 919 amino acids, ERalpha 595 amino acids, ERbeta 477 amino acids. Abbreviations: NTD, N-terminal domain; DBD, DNA binding 
domain; LBD, ligand binding domain. GR and MR have a highly conserved DBD at 94% similarity. The LBD is also more similar between 
GR and MR than GR and other members of the steroid receptor family although at 57% identity there are some important structural 
and functional differences in ligand binding affinity and specificity. The NTD is the least similar between members of the steroid receptor 
family. AdaHudson WH, Youn C, Ortlund EA. Crystal structure of the mineralocorticoid receptor DNA binding domain in complex with 
DNA. PLoS One 2014;9:e107000. [Adapted under Open Access License.]
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In vitro studies have previously found GR binds 
as an inverted dimer to 2 6  bp palindromic 
sequences, separated by a 3  bp spacer. These 
2 zinc fingers can therefore work together to 
promote GR binding with the first zinc finger 
binding to the first half of the palindromic se-
quence, and the second zinc finger enabling the 
binding of another GR to the other half of the 
palindromic sequence. Binding of a homodimer 
to the GRE of specific genes can promote trans-
activation. The NTD is the least well conserved 
domain but contains the ligand-independent 
AF1 site. AF1 in this region has been shown 
to communicate with coactivators, chromatin 
modulators, and basal transcription factors in-
cluding RNA polymerase II and TATA binding 
protein to initiate transcription. In the GR, the 
AF1 site remains relatively unfolded in the basal 
state, while it forms a significantly complex hel-
ical structure in response to binding to cofactors, 
including TBP and p160 coactivators (86).
The type 1 and type 2 corticosteroid receptors 
(MR and GR) were both cloned by 1987 (81,82) 
and were found to be very similar in structure and 
function. Notably, there is 94% DBD identity, and 
consequently the 2 receptors recognize and bind 
the same DNA regulatory sequences, termed glu-
cocorticoid regulatory elements (GREs). There is 
57% similarity in the LBD, with consequent func-
tional implications for differences in MR and GR 
ligand affinity and specificity. There has therefore 
been great speculation about MR versus GR spec-
ificity, particularly in tissues such as the hippo-
campus, where they are both abundantly expressed 
and often colocalized.
Ligand binding and activation dynamics
The endogenous glucocorticoids corticosterone 
and cortisol bind to MR with a 10-fold greater af-
finity than to GR (87–89). During periods of low 
circulating glucocorticoid levels (ie, during the 
inactive phase), which is the daytime for the noc-
turnal rat, the MR is already substantially occupied 
but the GR is not. GR becomes activated at higher 
glucocorticoid concentrations (ie, during the ac-
tive phase), or during a stress response (90,91). GR 
and MR also exhibit strikingly different dynamics 
in response to ultradian glucocorticoid pulses. 
During the high amplitude pulses of the active 
phase, the peak of each glucocorticoid pulse tran-
siently induces GR activation, resulting in hourly 
cycles of association/dissociation from DNA (92–
95). Pulses of glucocorticoid have therefore been 
defined as deterministic for ultradian transcrip-
tional activity, directing ordered recruitment of 
GR cofactors and the transcriptional machinery to 
glucocorticoid target genes (96), as shown in Fig. 5.
More extraordinary than the fast rate of GR 
recruitment of cofactors with the rising glucocor-
ticoid concentration is the rapid ejection of each 
component of the complex from the chromatin 
template during the falling phase of each pulse. 
Dissociation of GR from GREs in the DNA can be 
most simply explained by rapidly declining gluco-
corticoid levels during the falling phase of indi-
vidual pulses. Due to the relatively low affinity of 
GR for endogenous glucocorticoids, pulse nadir 
levels are not able to maintain GR activation and 
DNA binding throughout the interpulse interval. 
The underlying mechanism for this phenomenon 
has been addressed in studies into the inherent 
nature of transcription factor–DNA interactions 
(97). In contrast to the now outdated cooperative 
binding model, where a stable complex is formed 
between transcription factors and DNA, the current 
evidence based on 2 decades of research supports 
a much more dynamic exchange of transcription 
factors at the chromatin template (100–102), the 
phenomenon termed “rapid cycling.” The devel-
opment of a murine mammary carcinoma cell line 
with an expanded mouse mammary tumor virus 
(MMTV) long terminal repeat (800–1200 GRE 
sites in 1 locus, termed the MMTV array) enabled 
the first direct visualization of green fluorescent 
protein tagged GR (GFP-GR) recruitment to a reg-
ulatory DNA site large enough to be observed as 
a single bright focal point within a cell’s nucleus 
(101). Fluorescence recovery after photobleaching 
analysis could then be carried out to determine how 
rapidly activated GFP-GR molecules exchange at 
the array (102). Since the array rapidly regained its 
fluorescence after photobleaching, this indicates a 
rapid exchange between the existing photobleached 
GFP-GRs, and GFP-GRs from outside the defined 
photobleached area. The speed of recovery was 
consistent with GRs rapidly exchanging at the 
chromatin template in a matter of seconds (t1/2 = 5 
seconds), indicating that each GR binding event at 
the chromatin template occurred for 10 seconds to 
20 seconds before exchanging. While GR’s recruit-
ment was deemed to be highly stochastic, its ejec-
tion from the chromatin template was found to be 
dependent upon ATP and remodeling complexes 
(103,104). Therefore, GRs are believed to be ejected 
from the DNA template with each cycle of nucleo-
some repositioning as the chromatin is remodeled, 
before being stochastically and indiscriminately 
recruited to any one of the vast number of GRE 
sites throughout the genome. With each cycle 
of exchange, there is a probability of ligand loss, 
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leaving GR inactive and unable to reassociate with 
a GRE during the pulse nadir.
In contrast, MR has been demonstrated to 
remain maximally activated throughout the ul-
tradian interpulse interval (92) as shown in 
Fig.  6. The prolonged MR activation time is 
most likely due to a combination of its higher 
affinity and longer binding duration for endog-
enous glucocorticoids. While MR has not been 
reported to undergo rapid exchange at GRE sites, 
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Figure 5. Key concepts underpinning the GR ultradian cycling model. (A) Pulsatile GFP-GR recruitment and loss from the MMTV array is visualized in real time during 
pulsatile glucocorticoid (CORT) addition to the MMTV array containing cell line. (B) Fluorescence intensity at the array relative to fluorescence intensity of the surrounding 
nucleoplasm is quantified and plotted in blue over timing of corticosterone (CORT) pulse addition to the cell culture media plotted in red. Stavreva DA, Wiench M, John 
S, Conway-Campbell BL, McKenna MA, Pooley JR, Johnson TA, Voss TC, Lightman SL, Hager GL. Ultradian hormone stimulation induces glucocorticoid receptor-mediated 
pulses of gene transcription. CC-BY OA Nat Cell Biol 2009;11:1093–1102. © 2009, Springer Nature. (C) The temporal dynamics of the system has been interrogated in the 
pituitary cell line AtT20, where pulsatile recruitment of GR, P300, CBP, and RNA-Pol2 to the Per1 proximal GRE is relative to the transient pulses of acetylation at the same 
site. Conway-Campbell BL, George CL, Pooley JR, Knight DM, Norman MR, Hager GL, Lightman SL. The HSP90 molecular chaperone cycle regulates cyclical transcriptional 
dynamics of the glucocorticoid receptor and its coregulatory molecules CBP/p300 during ultradian ligand treatment. Mol Endocrinol 2011;25:944–954. Reproduced with 
permission. Mol Endocrinol 2011; 25:944–954 © 2011, Endocrine Society. (D) A schematic representation of GR activity at the chromatin template during pulsatile peak 
and nadir. At the pulse peak, GR undergoes rapid cycling to efficiently sample GRE sites across the genome. At this time, GR can be detected as “enriched” by ChIP assay at 
cell-specific target regulatory sites. At the pulse nadir, GR in no longer “enriched” at these same sites when assessed in ChIP assays. Subsequent cycles of GR activity ‘ON’ and 
“OFF” the chromatin template closely follow the peaks and troughs of each glucocorticoid pulse.
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it is likely that it also exhibits this activity as rapid 
exchange has been shown for all members of the 
nuclear receptor family tested so far. Presumably, 
rapid exchange of MR at the DNA template still 
continues even at much lower endogenous gluco-
corticoid concentrations. Importantly, the higher 
sensitivity of MR to glucocorticoids should not 
be misinterpreted as “constitutive” activity, as 
DNA binding was undetectable at extremely low 
glucocorticoid levels, in adrenalectomized rats 
for example. Interestingly, the MR was previ-
ously believed to remain at near maximal ligand 
occupancy during the circadian peak and nadir 
(87,88). However, more recent evidence suggests 
that MR exhibits circadian differences in binding 
to specific gene target regulatory elements, for 
example on the Fkpb5, Per1 and Sgk1 gene. In the 
presence of an acute stressor, the binding of MR 
at a regulatory element within Fkbp5 is also fur-
ther increased (91,105). A recent pulsatile gluco-
corticoid study by Rivers et al. (106), in the N2A 
neuronal cell line, confirmed that MR binding 
persisted during the interpulse interval at the 
majority of sites, whilst GR binding was lost at 
all sites. Additionally, the novel role for MR in 
augmenting GR’s transcriptional activation po-
tential at the pulse peak was identified in this 
study. This action of MR did not require its DNA 
binding, as it was able to be tethered to GRE 
sites by GR (106), potentially as a heterodimer 
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Figure 6. Dynamics of glucocorticoid receptor and mineralocorticoid receptor during ultradian glucocorticoid exposure. (A) 
Representative plot (adapted from (92)) showing temporal dynamics of hippocampal GR and MR activation times in relation to 2 intra-
venous corticosterone (CORT) pulses administered to adrenalectomized rats. (B) Area-proportional Venn diagrams show the proportions 
of GR and MR MACS2 binding sites that directly overlap by at least 1 bp between treatments (i) vehicle, (ii) CORT pulse, and (iii) washout 
period after CORT pulse. (C) University of California Santa Cruz Genome Browser image at the Fkbp5 gene shows comparison of mapped 
MR and GR ChIP-nexus data for each treatment group. Rivers CA, Rogers MF, Stubbs FE, Conway-Campbell BL, Lightman SL, Pooley JR. 
Glucocorticoid receptor-tethered mineralocorticoid receptors increase glucocorticoid-induced transcriptional responses. Endocrinology 
2019;160:1044–1056 (B and C; 108). Reproduced with permission Endocrinology 2019; 160:1044–1056. © Endocrine Society.
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(91,105,107,108) or other oligomeric form such 
as a tetramer as proposed by for GR (109).
Expression profiles of the corticosteroid 
receptors
The presence of corticosteroid binding sites in the 
brain was first discovered by Bruce McEwen and 
colleagues in the late 1960s (110), and a decade of 
research ensued to characterize these binding sites 
as 2 separate “populations” that are now known as 
GR and MR (111,112). It is now well accepted that 
GR is widely expressed throughout most cells and 
tissue types in the body. In the brain, GR has been 
found to be highly abundant in the hippocampus 
(HC) and medial prefrontal cortex (mPFC), as 
well as being expressed within the amygdala, areas 
that are associated with memory and learning 
processes (87,89,113). The pyramidal cells of the 
cornu ammonis (CA) 1 and CA2 regions of the HC 
have been shown to express GR at high levels, as 
well as the granular cells of the dentate gyrus (114). 
High levels of GR have also been shown in the cere-
bellar cortex, olfactory cortex, thalamus, hypothal-
amus, dorsal nucleus raphe, and locus coeruleus 
(87,89,115).
MR is generally reported to exhibit a more re-
stricted expression profile throughout the body, 
with notably high levels of expression in the kidney 
and adipose tissue (116). In the brain, MR expres-
sion has been reported in the prefrontal cortex, the 
medial and central amygdala, lateral septum, tha-
lamic nuclei, and hypothalamic nuclei (119–121). 
However, the highest expression of MR has been 
reported in the CA1, CA2, CA3, and dentate gyrus 
of the hippocampus (89). However, a recent study 
in the Parus major has shown that MR is prevalent 
across many areas of the brain including the locus 
coeruleus and the oculomotor nerve (120), there-
fore it may still remain to be seen how widespread 
MR expression is in humans and experimental 
rodents.
GR and MR action in the brain—HPA axis 
regulation
When de Kloet and Reul (87) originally found 
that MRs were substantially occupied with li-
gand in basal conditions during the circadian 
nadir, they hypothesized that MR may have a role 
in maintaining the HPA axis set point. In 1989, 
Mary Dallman showed this to be case, reinstating 
normal hypothalamic and pituitary set points in 
adrenalectomized rats by replacing corticosterone 
at a dose that activated MR but not GR (121). The 
MR antagonist RU28318 administered directly 
into the brain of rats, via Intracerebroventricular 
(ICV) or intrahippocampal infusion, increased 
basal HPA axis activity and potentiated the ini-
tial rise in ACTH and corticosterone secretion in 
response to stress (122,123). In humans, systemic 
treatment with the MR antagonist spironolactone 
also increased basal and stress induced cortisol 
secretion (124). In contrast, GR antagonism with 
RU38486 had no effect on basal HPA axis activity, 
which may be expected as GR is not activated by the 
low glucocorticoid levels secreted during the circa-
dian nadir in basal conditions. The use of RU38486 
was however able to elucidate GR’s major role in 
the response to stress, as antagonist treatment at-
tenuated the initial HPA stress response and there-
fore resulted in prolonged cortisol secretion due to 
inhibition of GR negative feedback (122,123).
Role of pulsatile activity in the stress response
In the late 1990s, Windle et al. (20) noted that his 
experimental rats’ HPA response to a mild psycho-
logical stressor (10 minutes of 99 db of white noise) 
was variable, with the corticosterone response 
diverging into 2 distinct groups as “responders” and 
“non-responders’. Subsequent post hoc analysis of 
each rat’s corticosterone profile relative to the onset 
of the noise stress revealed an extremely interesting 
finding. When the stress coincided with the rising 
phase of a pulse, adrenal corticosterone secretion 
was potentiated. When the stress coincided with 
the falling phase of a pulse, adrenal corticosterone 
secretion was inhibited. Sarabdjitsingh et al. (125) 
went on to further interrogate this observation, by 
introducing exogenous pulses of corticosterone 
back into adrenalectomized rats and timing the 
onset of a noise stress to either the rising or falling 
phase of a pulse. Consistent with Windle’s orig-
inal findings, the HPA axis response (measured 
by ACTH production in this case) was potentiated 
in the rising phase, and significantly attenuated 
in the falling phase of the infused corticosterone 
pulse. Not only was the HPA response sensitive to 
the phase of the pulse, but so too was neuronal ac-
tivation in the pituitary, paraventricular nucleus, 
amygdala, and hippocampus, as well as the behav-
ioral coping response to the stressful encounter.
Although it might seem strange that respon-
siveness of the HPA depends to a degree on an 
hourly phase, it is easier to think of this in terms of 
maintaining system responsiveness. Thus in classic 
pharmacology constant exposure to a ligand often 
results in downregulation of response, similarly 
if we compare response parameters between con-
stant infusion of corticosterone of the same dose 
given in physiological pulses, we find that during 
the “constant corticosterone infusion,” all 3 stress 
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response parameters measured were significantly 
impaired in comparison to both rising and falling 
phase pulsatile. Therefore ultradian glucocorticoid 
oscillations appear to be critical for the mainte-
nance of normal physiological, neuronal, and be-
havioral reactivity to stress.
Learning and memory
The role of glucocorticoids in hippocampal 
memory function has historically been one of the 
most well-described effects of glucocorticoids 
on the brain. We now know that stress-induced 
glucocorticoids enhance memory consolidation 
and impair memory retrieval, as well as induce a 
shift from hippocampal controlled cognitive pro-
cessing to dorsal striatum controlled cognitive pro-
cessing. Pharmacological studies in rats originally 
tested in the spatial memory task of the Morris water 
maze showed that blockade of GR after learning 
prevented memory consolidation (126,127). The 
GR-mediated effects were dependent upon gene 
transcription and could be observed with systemic, 
ICV and intrahippocampal site-specific admin-
istration of the GR antagonists. Memory consol-
idation was also abolished in mice with a point 
mutation in the GR dimerization domain (128).
In the same Morris water maze tests, blockade 
of MR affected memory retrieval and the se-
lection of behavioral search strategy (126,127). 
Molecular manipulation of MR by knockdown or 
overexpression in mice also altered exploratory 
and searching behavioral strategy in a stimulus 
response task (131). Interestingly, similar behav-
ioral observations have been made in humans 
(132–135), where MR plays a role in switching be-
tween simple effective strategies and complex flex-
ible strategies when required in different tasks, and 
particularly in stressful situations. These studies 
utilized functional magnetic resonance imaging, 
showing the switch between hippocampal activity 
and dorsal striatum activity, while tasks of different 
complexities were undertaken.
Taken together, these data from pharmacolog-
ical, behavioral, and functional imaging studies in 
rodents and humans highlight an important role 
for the dual GR system in cognitive processing. 
However, little was known about the role of the 
glucocorticoid pattern in memory and learning 
until a recent study by Kalafatakis and colleagues 
(134,135). In this study, a double-blinded, placebo-
controlled, crossover design in healthy volunteers 
was used to assess how different patterns of hydro-
cortisone affect emotional and cognitive processes 
in these otherwise healthy individuals. Fig. 7 shows 
a schematic of the experimental protocol. Each 
volunteer took part in 3 5-day, randomized order, 
block and replace studies. Endogenous cortisol was 
blocked with metyrapone and hydrocortisone was 
replaced using either of 3 options: (1) standard oral 
dosing, (2) subcutaneous pump delivery with both 
circadian and ultradian rhythm components, and 
(3) subcutaneous pump delivery with a circadian 
rhythm, but no ultradian rhythm.
On the 5th day of each treatment arm, cog-
nitive performance was measured in an n-back 
working memory task. Interestingly, no signifi-
cant differences were found between the 3 treat-
ment arms when the cognitive demands of the 
working memory task were relatively low in the 
2-back task. However, when the complexity of the 
task increased to 3-back, significant differences 
were revealed in the subject’s ability to retain their 
working memory capacity. Only during pulsatile 
replacement could subjects perform well under 
the increased cognitive demand, indicating a role 
for optimal pulsatile glucocorticoid replacement 
in retention of working memory capacity under 
increased cognitive demands.
Ultradian glucocorticoid pulses balance 
glutamatergic transmission and synaptic 
plasticity
The emerging evidence for rapid nongenomic MR 
actions (136) combined with slower genomic GR 
actions (137) provides a physiologically realistic 
mechanism to explain the dynamic glucocorti-
coid control of glutamatergic neurotransmission. 
The effects on neuronal excitability are not only 
dose dependent, indicating distinct GR- and 
MR-dependent actions, but also operate in different 
time domains (137). A series of elegant studies by 
Marian Joëls’ group (138) showed that a single 
corticosterone pulse altered baseline transmission 
during the interpulse interval, by increasing syn-
aptic enrichment of glutamate receptors, altering 
responsiveness to spontaneously released gluta-
mate, and preventing subsequent LTP induction. 
A second pulse normalized glutamate transmission 
and synaptic plasticity. This phenomenon has been 
termed stress metaplasticity, a mechanism whereby 
response to glucocorticoid pulses can switch from 
excitatory to inhibitory depending on the recent 
“stress” history. Consistent with how vividly emo-
tionally arousing experiences are encoded into 
memories, neurons in the basolateral amygdala 
are highly sensitive to stress plasticity (139,140). 
In the basolateral amygdala, it has been further 
demonstrated that the duration of the transient 
increase in spontaneous glutamate transmission 
depends on both severity and duration of stress, 
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and is followed by a prolonged suppression in ex-
citability (141).
Ultradian rhythmicity is necessary for normal 
emotional processing in man
The molecular data above together with the be-
havioral experiments in rodents replaced with 
different corticosterone patterns provide com-
pelling evidence that the amygdala is highly 
sensitive to dysregulated patterns of glucocorti-
coid exposure, but how does this translate into 
effects in the human brain. Using their block and 
replace protocol on healthy volunteers (135), 
Kalafatakis and colleagues also interrogated how 
different patterns of cortisol affected processing 
of emotionally salient information (134). Using 
a functional magnetic resonance imaging pro-
tocol assessing neural processing of emotional 
faces (IFEPT), the authors clearly demonstrated 
that different patterns of cortisol replacement 
had differential effects on the functional connec-
tivity of areas underlying emotional processing 
including the amygdala, dorsal striatum, insula, 
and orbitofrontal cortex. This was reinforced by 
findings that nonpulsatile cortisol replacement 
was associated with a negative bias to ambiguous 
cues, and differences in recognition accuracy 
of emotional cues. These findings strongly sup-
port the notion that glucocorticoid rhythmicity 
modulates the neural dynamics underlying mood 
and anxiety.
Altered HPA Dynamics in Disease
Cushing’s syndrome
Cushing’s syndrome (CS) is characterized by ex-
cess levels of circulating glucocorticoid, most com-
monly due to exogenous treatment, which will be 
discussed in detail further into this review. More 
rarely, but posing a clinically important problem, 
CS is caused by unregulated excessive produc-
tion of ACTH by a pituitary tumor (Cushing’s di-
sease) (142,143), by ectopic secretion of ACTH, by 
cortisol secreting adrenal cortical tumors, or by 
multiple hypersecreting nodules in both adrenal 
cortices (primary macronodular adrenocortical 
hyperplasia) (144,145). While benign appar-
ently nonsecreting adrenocortical tumors 
(incidentalomas) are found in up to 7% of the pop-
ulation (146), it is becoming clear that a proportion 
of these do have dysregulated cortisol secretion 
which can result in mild—but probably signifi-
cant—hypercortisolemia (146).
Along with myriad metabolic adverse effects and 
cardiovascular risks (147), patients with CS demon-
strate deficits in memory, and a wide range of cog-
nitive impairments and mood disorders (148,149) 
as well as predisposition to anxiety and depres-
sion (150). This is most marked in older patients 
and in females (151,152). Although there is some 
preservation of pulsatility in Cushing’s patients, 
the 24-hour secretory pattern is characterized by 
an absence of the normal circadian variation and 
Figure 7. Schematic representation of experimental design and patterns of hydrocortisone replacement. (A) Protocol design and ABS 
profiles showing the circulating cortisol pattern with either (B) oral hydrocortisone dosing, or subcutaneous pump infusion of (C) pulsa-
tile hydrocortisone or (D) constant hydrocortisone. From (134) and (135).
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a failure of the plasma cortisol level to fall below 
2 µg/dL between 23.00 and 03.00 hours (153).
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is a condition asso-
ciated with increased prevalence of cardiovascular 
disease, metabolic syndrome and glucose intoler-
ance (154), all symptoms associated with gluco-
corticoid excess. Henley et al (155) used frequent 
automated blood sampling in OSA patients, and 
found a marked disruption in HPA activity with 
significantly longer duration of ACTH and cortisol 
secretory episodes and larger pulsatile hormone 
release. Patients were reassessed after 3  months 
of compliant continuous positive airway pressure 
therapy, and HPA dynamics were found to nor-
malize compared with untreated OSA. This study 
highlighted some important points about regu-
lation and dysregulation of this highly dynamic 
system, as well as its recovery. It was hypothesized 
that one of the likely mechanisms underlying 
OSA-related HPA dysregulation was the poten-
tial damage that sleep disruption and hypoxic 
episodes can cause to the hippocampal forma-
tion, a major integrator of HPA negative feedback. 
Hippocampal neurons are highly susceptible to hy-
poxic/metabolic insults, and OSA patients exhibit 
hippocampal damage and cognitive deficits as a 
result (156). OSA patients also exhibit sympathetic 
nervous system hyperactivity (157), which can di-
rectly act on the adrenal cortex to alter adrenal re-
sponsiveness (158), as well as alter hippocampal 
corticosteroid receptor expression levels (159). The 
resulting net effect may be impaired rapid negative 
feedback, longer secretory episodes and as a result 
higher nadir levels of cortisol between individual 
pulses of cortisol release (160).
Depression
According to the corticosteroid receptor hypothesis 
of depression (160) changes in the set point of the 
HPA axis are found in many patients with depres-
sion. In particular, altered regulation of ACTH and 
cortisol secretory activity, along with impaired cor-
ticosteroid receptor signaling have been postulated 
to underpin depressive psychopathology (161,162). 
In patients where neuroendocrine abnormality 
persisted, risk of relapse or resistance to treat-
ment was much higher (163,164), supporting the 
validity of “psychoneuroendocrine” strategies 
(167–169). However, using a 24-hour frequent au-
tomated blood sampling protocol, Elizabeth Young 
(12,168) found that only 24% of a patient cohort 
of 25 depressed premenopausal women exhibited 
hypercortisolemia. In comparisons with matched 
controls, there was no difference in mean cor-
tisol either between the patient group as a whole 
or those patients meeting criteria for atypical de-
pression. Only the patients meeting criteria for en-
dogenous depression showed increased cortisol. 
Reports of enlarged adrenal glands (169,170), and 
impaired negative feedback in depressed patients 
(171,172) have led to the theory that the level of 
impairment is at the GR-dependent negative 
feedback, either centrally or the level of pituitary. 
Treatment interventions have included CRH re-
ceptor antagonists (173), GR antagonists (174,175), 
and cortisol synthesis inhibitors (176,177). More 
recently, targeted antagonism of the GR chaperone 
protein FKBP51 (178,179) with a selective inhib-
itor (180,181) has proved promising.
Infection, trauma, critical care medicine, and the 
inflammatory response
In healthy individuals, adrenal glucocorticoids 
exert anti-inflammatory and immune modulating 
actions (182–184). The acute increase in adrenal 
glucocorticoid secretion in response to infection, 
injury or trauma is therefore thought to be an 
adaptive homeostatic mechanism to prevent im-
munological over-reaction (185). Proinflammatory 
cytokines are rapidly induced in response to infec-
tion, injury or trauma and act to induce systemic 
or localized immune response. These factors also 
act directly on the adrenal gland in a mechanism 
signaling the body’s requirement for increased 
production and secretion of glucocorticoid hor-
mone (186,187). Activated GR then acts in a well-
characterized mechanism termed transrepression 
to directly switch off proinflammatory genes and 
inhibit the inflammatory actions of the cytokines, 
at target sites.
An excellent example of the role of plasticity 
within the HPA axis is the response to coronary 
artery bypass graft surgery. Gibbison et  al. (188) 
used perioperative automated blood sampling 
to measure cortisol at 10-minute intervals and 
ACTH at 60-minute intervals over a 24-hour pe-
riod. ACTH and cortisol both initially rose to ex-
tremely high levels during the final stages of the 
surgery, but ACTH returned toward preopera-
tive levels after the surgery was completed while 
supraphysiological cortisol pulses continued until 
the end of the 24-hour sampling time. While co-
ordinated timing of ACTH and cortisol pulses was 
maintained in all individuals, the sensitivity of 
the adrenal gland to ACTH appeared to increase 
markedly after surgery so that very high levels of 
cortisol were produced despite low basal ACTH 
levels, a phenomenon which had been previously 
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noted (189) but not interrogated with the de-
tailed methodology of frequent blood sampling 
(190) or at the mechanistic level until the study of 
Gibbison and colleagues (188). The mechanism 
suggested for this striking adrenal hypersensi-
tivity is mediated by systemic inflammatory signals 
(193–195) inducing cytokine-mediated sensitiza-
tion of adrenal responses to ACTH (194). In sup-
port of this, rats treated with the potent activator of 
immune response, LPS, exhibit similarly increased 
adrenal sensitivity resulting from changes in the 
regulation of both stimulatory and inhibitory 
intra-adrenal signaling pathways (69) as shown 
in Fig. 8. Whether the ACTH cortisol dissociation 
after coronary artery bypass graft surgery is a solely 
cytokine mediated effect or acts in concert with a 
combination of factors is the subject for further 
study (195) but it provides an excellent example of 
the body’s survival mechanisms at play.
This highly advantageous adaptive process of 
immune modulation of adrenal glucocorticoid 
secretion (187) also unfortunately has the poten-
tial to become maladaptive in cases of chronic in-
flammatory disease (196,197). In an experimental 
rat model of adjuvant-induced arthritis, corti-
costerone dynamics are severely affected (198). 
Higher frequency pulses are detected throughout 
the 24-hour period, with a loss of the normal cir-
cadian nadir in corticosterone secretion (47). This 
form of hyperactive HPA axis has similarities to the 
high amplitude pulses detected in rats subjected 
to 6 weeks of 200 lux bright light (61), which is a 
chronic stressor for the nocturnal animals as well 
as disrupting their circadian cues. There are no 
parallel studies looking at 24-hour levels of cor-
tisol in man, and although studies of cortisol levels 
in rheumatoid arthritis patients have not always 
produced consistent results, there is evidence that 
Figure 8. Crosstalk between the adrenal steroidogenic regulatory network and the immune pathway. During the inflammatory re-
sponse induced by LPS, the synthesis of glucocorticoids in adrenocortical cells is modulated by the immune pathway through cytokines. 
The SRN, in turn, feeds back upon the cytokines signaling pathways. The Spiga et al. mathematical model has therefore also inte-
grated these cytokine effects on the steroidogenic response to LPS. Their model predicts sustained induction of adrenal glucocorticoid 
(A-CORT) and inhibition of pGR, transient induction of SF-1 and StAR transcription, transient inhibition of DAX-1 gene expression, and 
SF-1, StAR, and DAX-1 mRNA and protein dynamics that were then shown experimentally in LPS treated rats. From (69). Spiga F, Zavala 
E, Walker JJ, Zhao Z, Terry JR, Lightman SL. Dynamic responses of the adrenal steroidogenic regulatory network. Proc Natl Acad Sci U S 
A 2017;114:E6466–E6474. CC-BY OA. 2017, Springer Nature
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plasma cortisol levels may be elevated with a loss 
of circadian nadir and reduced reactivity to HPA 
axis stimulation (199,200). This raises the impor-
tant question of whether chronic inflammation 
induces a form of glucocorticoid resistance, which 
then creates a vicious cycle in disease progression.
Treatment with Synthetic Glucocorticoids
Synthetic glucocorticoids are one of the most 
commonly prescribed classes of drugs, primarily 
for treating inflammatory conditions, from skin 
conditions such as dermatitis to rheumatological 
diseases such as systemic lupus erythematosus, 
Crohn’s disease, ulcerative colitis, rheumatoid ar-
thritis and asthma. In the UK and US, nearly 2% 
of the adult population use oral glucocorticoids 
at any given time (201,202). Treatment with syn-
thetic glucocorticoids results in raised levels of 
glucocorticoids throughout the day with a loss of 
both ultradian and circadian oscillations (134). 
Side effects are multiple, across metabolic, skeletal, 
cardiovascular, and immune systems, but also af-
fecting the central nervous system with patients 
often complaining of changes to mood, with a pro-
portion of these reporting bouts of depression, and 
in severe cases, mania (203). Interestingly, reports of 
depression and psychiatric illness reported with syn-
thetic glucocorticoid use, are not dissimilar to those 
reported by patients with Cushing’s disease and 
CS, who present with elevated levels of glucocorti-
coid hormones throughout the day (204,205). Sleep 
disturbances are commonly reported and studies 
have revealed that memory is significantly impaired 
with long-term prednisolone treatment (206–209).
Potential for Chronotherapy: A Pulsatile 
Replacement Strategy in Addison’s Disease 
as Proof of Principle
Prior to the development of steroid replacement 
therapy, adrenal insufficiency resulted in 10% mor-
tality rates (210). Glucocorticoid replacement had 
a miraculous effect—but it is often overlooked that 
standard replacement therapy is also associated 
with an increased mortality, with a standardized 
mortality ratio over 2.  Furthermore, standard re-
placement therapy results in impaired health-
related quality of life (211–216), adverse metabolic 
and cardiovascular risk profiles (217), increased 
levels of proinflammatory cytokines (218), and—
most disabling for many patients—reduced ac-
tivity, low motivation, and mental fatigue with 
associated high levels of unemployment and disa-
bility benefits (214,219–223).
We are now at a critical point for the develop-
ment of safer and more effective glucocorticoid 
replacement therapy. One way forward is the de-
velopment of physiological pulsatile replacement 
therapy using miniature nanopumps or subcuta-
neous reservoirs. We have shown proof of prin-
ciple that subcutaneous infusions can reproduce 
normal circadian and ultradian rhythmicity 
(224). Furthermore, we have gone on to compare 
responses of normal volunteers to physiolog-
ical circadian rhythms of cortisol either with or 
without pulsatility of the infused cortisol (134). In 
this study the pulsatile infusions promoted better 
quality of sleep, improved performance of working 
memory, and also resulted in differential effects 
on attentional bias to and recognition of emo-
tional cues. This was also associated with differen-
tial responses in functional connectivity of brain 
regions which process emotional responses. The 
importance of these effects in longer term replace-
ment therapy in patients with Addison’s disease is 
currently under investigation.
It is not only replacement therapy that 
might benefit from ultradian chronotherapy. 
Glucocorticoid hormones are currently prescribed 
to over 1% of the population (201) and side effects 
are apparent even after short-term (<  30  days) 
duration (225), while even “side-effects sparing 
corticosteroids” cause weight gain, the metabolic 
syndrome and adverse cardiometabolic effects 
(226). It is becoming clear that we need to improve 
steroid therapy and whether the administration 
of oscillating levels of glucocorticoids can modify 
the ratio of wanted effects to unwanted side-effects 
needs to be investigated.
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